Baxter International said global net sales for 2024 totaled $10.64 billion, an increase of 3% on a reported basis and 3% on a constant currency basis compared to 2023. U.S. sales were $5.85 billion, up 1%, and international sales were $4.79 billion, up 5% on a reported basis.

1. 01

   Baxter International said global net sales for 2024 totaled $10.64 billion, an increase of 3% on a reported basis and 3% on a constant currency basis compared to 2023. U.S. sales were $5.85 billion, up 1%, and international sales were $4.79 billion, up 5% on a reported basis.

2. 02

   Baxter said net loss attributable to Baxter stockholders in 2024 totaled $(649) million, or $(1.27) per diluted share, and special items reduced net income by $2.13 billion. Net loss from continuing operations was $(326) million, and the impact of special items was $1.29 billion.

3. 03

   Baxter completed the sale of its Kidney Care business to Carlyle on January 31, 2025 for an aggregate purchase price of $3.80 billion in cash, receiving approximately $3.71 billion in pre-tax cash proceeds at closing. As of February 21, 2025, the company repaid $3.13 billion of short- and long-term indebtedness.

4. 04

   Baxter said operating cash flows from continuing operations in 2024 were $819 million, compared to $1.21 billion in 2023, and cited an increase in net loss from continuing operations and higher annual payouts under employee incentive plans based on 2023 performance as factors. As of December 31, 2024, cash and cash equivalents totaled $1.76 billion, and long-term debt and finance lease obligations, including current portions, and current liabilities totaled $13.13 billion.

Key figures

Fiscal year ended December 31, 2024

Revenue

$10.6B

Operating income

$14M

Net income

−$649M

EPS

−$1.27

Gross profit

$4.0B

Operating cash flow

$1.0B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.